Literature DB >> 26080752

MDS and GCA: a prognostic dilemma.

Neha G Narula1, Andy Abril2.   

Abstract

A number of autoimmune disorders, such as large vessel vasculitis, have been recognized in patients who have myelodysplastic syndrome (MDS) and myeloproliferative syndrome (MPS). The influence of an autoimmune disorder on the prognosis of patients who have MDS and MPS remains to be determined. We report three cases of myelodysplastic syndrome and large vessel vasculitis seen at our institution and provide a brief literature review of the two disease processes. More studies are needed to determine the pathophysiology of the underlying diseases and whether there truly is a relationship between the disease entities and to discover better markers for disease assessment.

Entities:  

Keywords:  Autoimmune; Myelodysplastic syndrome; Myeloproliferative syndrome; Vasculitis

Mesh:

Year:  2015        PMID: 26080752     DOI: 10.1007/s10067-015-2993-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  35 in total

1.  Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?

Authors:  Giovanni Barosi; Umberto Magrini; Robert Peter Gale
Journal:  Leuk Res       Date:  2010-06-09       Impact factor: 3.156

2.  Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?

Authors:  Hans Carl Hasselbalch
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

3.  Surgical pathology of noninfectious ascending aortitis: a study of 45 cases with emphasis on an isolated variant.

Authors:  Dylan V Miller; Phillip A Isotalo; Cornelia M Weyand; William D Edwards; Marie-Christine Aubry; Henry D Tazelaar
Journal:  Am J Surg Pathol       Date:  2006-09       Impact factor: 6.394

Review 4.  Large vessel vasculitis with myelodysplastic syndrome.

Authors:  Takayuki Katsuyama; Haruhito Adam Uchida; Kishio Toma; Yoshinobu Maeda; Daisho Hirota; Ryoko Umebayashi; Ken-Ei Sada; Hirofumi Makino
Journal:  Intern Med       Date:  2014       Impact factor: 1.271

5.  Vessel-specific Toll-like receptor profiles in human medium and large arteries.

Authors:  Olga Pryshchep; Wei Ma-Krupa; Brian R Younge; Jörg J Goronzy; Cornelia M Weyand
Journal:  Circulation       Date:  2008-09-02       Impact factor: 29.690

Review 6.  The immunopathology of giant cell arteritis: diagnostic and therapeutic implications.

Authors:  Cornelia M Weyand; Y Joyce Liao; Jörg J Goronzy
Journal:  J Neuroophthalmol       Date:  2012-09       Impact factor: 3.042

7.  Occupational and socio-economic risk factors for giant cell arteritis: a nationwide study based on hospitalizations in Sweden.

Authors:  B Zöller; X Li; J Sundquist; K Sundquist
Journal:  Scand J Rheumatol       Date:  2013-07-02       Impact factor: 3.641

8.  Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica: a coincidental coexistence or a causal relationship?

Authors:  G Espinosa; J Font; F J Muñoz-Rodríguez; R Cervera; M Ingelmo
Journal:  Clin Rheumatol       Date:  2002-08       Impact factor: 2.980

Review 9.  Autoimmune myelofibrosis: report of three cases and review of the literature.

Authors:  Rita Rizzi; Domenico Pastore; Arcangelo Liso; Grazia M Liuzzi; Anna M Dalena; Giorgina Specchia; Rosalia Ricco; Vincenzo Liso
Journal:  Leuk Lymphoma       Date:  2004-03

10.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.